Ignite Creation Date:
2025-12-24 @ 4:27 PM
Ignite Modification Date:
2025-12-30 @ 3:05 AM
Study NCT ID:
NCT01576666
Status:
COMPLETED
Last Update Posted:
2020-12-19
First Post:
2012-04-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Dose Escalation | View |
| None | Safety | View |
| None | Preliminary Efficacy | View |
| None | Advanced Solid Tumors | View |
| None | Metastatic Breast Cancer | View |
| None | Advanced Pancreatic Adenocarcinoma | View |
| None | Metastatic Colorectal Cancer | View |
| None | Recurrent Glioblastoma Multiforme | View |
| None | Gastric Cancer | View |
| None | Gastroesophageal Junction Cancer | View |
| None | Triple Negative Metastatic Breast Cancer | View |
| None | Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Dose escalation | View |
| None | Maximum Tolerated Dose | View |
| None | MTD | View |
| None | Safety Expansion | View |
| None | Safety | View |
| None | Preliminary Efficacy | View |
| None | Objective Response Rate | View |
| None | Early progression rate | View |
| None | PI3K activation | View |
| None | Combination Treatment | View |
| None | Hedgehog Signaling Pathway | View |
| None | Smoothened inhibitor | View |
| None | Phosphoinositide-3' kinase | View |
| None | Phosphatase signaling pathway | View |
| None | Advanced solid tumors | View |
| None | metastatic breast cancer | View |
| None | advanced pancreatic adenocarcinoma | View |
| None | metastatic colorectal cancer | View |
| None | recurrent glioblastoma multiforme | View |
| None | gastric cancer | View |
| None | gastroesophageal junction cancer | View |
| None | triple negative metastatic breast cancer | View |
| None | hormone receptor positive (ER+/PR+, and Her2-) metastatic breast cancer | View |